BML-277|516480-79-8|(Chk2 Inhibitor II)-陌孚医药/Medlife

您当前的位置：

BML-277 (Synonyms: Chk2 Inhibitor II)

目录号: PL13952 纯度: ≥98%

CAS No. :516480-79-8

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	BML-277
中文别名	2-[4-(4-氯苯氧基)苯基]-1H-苯并咪唑-5-甲酰胺;2-[4-(4-氯苯氧基)苯基]-1H-苯并咪唑-5-羧酰胺;BML-277 抑制剂
英文名称	BML-277
英文别名	2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-6-carboxamide;1H-benzimidazole-5-carboxamide, 2-[4-(4-chlorophenoxy)phenyl]-;2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxylic acid amide;2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide;BML-277;2-(4-(4-CHLOROPHENOXY)PHENYL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE;2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide;Chk2 Inhibitor II;BML277;C 3742;2-[4-(4-Chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide
Cas No.	516480-79-8
分子式	C₂₀H₁₄N₃O₂Cl
分子量	363.80
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	BML-277 是一种选择性的检测点激酶 2 (Chk2) 抑制剂，IC₅₀ 为 15 nM。
生物活性	BML-277 is a selective checkpoint kinase 2 (Chk2) inhibitor with an IC 50 of 15 nM.
性状	Solid
IC50 & Target[1][2]	Chk2 15 nM (IC50)
体外研究(In Vitro)	BML-277 is an ATP-competitive inhibitor of Chk2 that dose dependently protects human CD4 and CD8 T-cells from apoptosis due to ionizing radiation. BML-277 efficiently rescues both T-cell populations from radiation-induced apoptosis in a dose-dependent manner with an observed EC50 of 3?7.6 μM. The concentration of BML-277 required for radioprotection is consistent with the biochemical measurement of chk2 inhibition. Providing theKm of ATP for Chk2 is determined to be 99 μM and the Ki for BML-277 is 37 nM, and assuming that the intracellular ATP concentration is 10 mM, a 5 μM concentration of BML-277 would be expected to produce 42% inhibition of intracellular chk2. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Arienti KL, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.

溶解度数据	In Vitro: DMSO : 22.22 mg/mL (61.08 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品